Naperville, IL -- (ReleaseWire) -- 05/08/2014 -- Reportstack, provider of premium market research reports announces the addition of Triptans (Migraine) - Forecast and Market Analysis to 2023 market report to its offering
Triptans (Migraine) - Forecast and Market Analysis to 2023
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
Triptans are indicated for the acute treatment of a migraine attack once it has begun, as well as its associated symptoms such as photophobia, phonophobia and nausea. Triptans are selective serotonin (5-HT) receptor agonists that display high affinity for the 5-HT1 class of receptors. Specifically these are the 5-HT1B and 5-HT1D receptor subtypes, as well as some having varying affinity for the 5-HT1F receptor subtype. Each of the individual subtypes has a different mechanism of action. The 5-HT1B subtype causes vasoconstriction in the cranial circulation and in the heart, whereas 5-HT1D subtypes are located on CNS neurons and trigeminal nerve endings.
- Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Triptans including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Beta blockers for the top seven countries from 2012 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Migraine
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Triptans performance
- Obtain sales forecast for Beta blockers from 2012-2023 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)
To view the table of contents for this market research report please visit